Divor Kiseljak | Chief Operating Officer
Excellgene

Dr. Divor Kiseljak earned his Master’s in Molecular Biology from the University of Zagreb in 2008 and went on to complete his PhD at EPFL in Lausanne, where he specialized in protein expression and cell line development. His research on transient gene expression in HEK cells, including achieving a notable 2 g/L protein yield, has been widely recognized, accumulating over 350 citations.
In 2012, Dr. Kiseljak joined ExcellGene as a Principal Scientist, leading the development of CHO- and HEK-based cell lines and processes for a range of innovative biologics and biosimilars. Known for his collaborative approach and strong leadership, he progressed to Chief Operating Officer in 2022, where he continues to drive the company's advancements in biopharmaceutical development.